In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire: Remodeling Specialty Pharma

Executive Summary

As biotech and Big Pharma invade spec pharma's traditional in-licensing ground, Shire's challenge is to bring investors along with its necessary strategic evolution. They've succeeded so far. Other spec pharma firms should take note of how.
Advertisement

Related Content

Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
For Shire, Life After Adderall XR? Yes
Baked-In Goodness: Shire Buys New River for $2.6 Billion
Cephalon: Can Spec Pharma do R&D?
Shire/TKT: The Price of Diversification
Shire/TKT: The Price of Diversification
Shire: Proving the Specialty Model
Endo: Accessing Primary Care through Specialist Marketing
Shire Shifts Upstream

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel